Small Molecule Factor D Inhibitors for Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD), lack effective small molecule inhibitors for Factor D, leading to inadequate management of excessive complement activation and associated inflammatory responses.
Innovation Solution
Development of active compounds, specifically those of Formula I, Formula I′, or Formula I″, or their pharmaceutically acceptable salts, which act as inhibitors of the complement Factor D cascade, capable of treating disorders associated with the alternative, classical, or lectin pathways, and can be administered alone or in combination with other pharmaceutical agents to reduce inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement-mediated disorders are used, then some therapeutic effect is achieved, but effective small molecule inhibitors for Factor D are lacking, leading to inadequate management of excessive complement activation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prolyl compounds through systematic variation of substituents (R1-R6, R12-R17) to optimize Factor D inhibition activity. This involves changing molecular parameters such as substituent types, positions, and configurations to achieve potent and selective complement pathway inhibition, thereby resolving the lack of effective small molecule inhibitors.
Solution Approach 2:
The patent employs composite molecular structures combining prolyl core frameworks with diverse substituent groups (aromatic rings, heterocycles, alkyl chains, functional groups). These composite compounds integrate multiple structural elements to achieve both high affinity for Factor D and desirable pharmacological properties, addressing the inadequacy of current single-structure approaches.
2Speed
If the alternative pathway of the complement cascade is activated, then rapid response to pathogenic organisms is achieved, but excessive activation leads to cellular damage and inflammatory disorders
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that selectively bind to and inhibit Factor D, the key enzyme in the alternative pathway. These compounds act as mediators to modulate complement activation, allowing sufficient immune response while preventing excessive activation that causes cellular damage. The compounds serve as controllable intermediaries between pathogen detection and complement-mediated cellular effects.
Solution Approach 2:
The patent applies parameter changes by developing compounds with specific inhibition constants and selectivity profiles that allow fine-tuning of complement pathway activity. By adjusting molecular parameters of the inhibitors, the system can maintain rapid response capability while controlling the degree of activation to prevent harmful effects.
3Reliability
If Factor H is mutated, then genetic studies show increased risk of macular degeneration, but without adequate functioning Factor H, the alternative pathway is overly activated leading to cellular damage
Solution Approach 1:
The patent introduces small molecule inhibitors as artificial intermediaries that compensate for defective Factor H function. These compounds directly inhibit Factor D, the enzyme responsible for alternative pathway activation, thereby replacing the lost regulatory function of mutated Factor H and preventing uncontrolled complement activation in genetically susceptible individuals.
4Reliability
If eculizumab is used to treat PNH, then complement activation is reduced, but patients remain anemic and require life-long intravenous injections
Solution Approach 1:
The patent replaces the mechanical/administrative system of life-long intravenous injections with orally bioavailable small molecule compounds. By developing compounds that can be administered systemically through non-invasive routes and achieve sustained inhibition, the patent eliminates the need for repeated hospital visits and intravenous access, dramatically improving treatment convenience while maintaining efficacy.
Solution Approach 2:
The patent employs small molecule compounds that can be administered in discrete oral doses rather than requiring continuous intravenous therapy. Each dose provides temporary but sufficient inhibition, allowing patients to manage treatment independently at home, replacing the expensive and inconvenient infrastructure of lifelong hospital-based infusions.
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I″ and I′″ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.